The excitement over Canadian-based YM and its presentation of data from phase I and II clinical trials at ASCO centers not only on its positive data on myelofibrosis but on indications its JAK inhibitors may also have applications in solid tumors, as well as inflammatory diseases, says Chrystyna Bedrij, biotech analyst at Griffin Securities.
FORBES: YM Biosicences: Its Data at ASCO On Drug for Bone Marrow Disorders Catapults Its Stock